News und Analysen
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced a wholly owned subsidiary of the
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that nonclinical data describing the expression of fibroblast activating protein (FAP) in a variety of solid tumor types will be presented during the
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1
Sensorion Hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Quantum Genomics Publishes 2021 Half-year Results and Reviews its Clinical Activity
Quantum Genomics Publishes 2021 Half-year Results and Reviews its Clinical Activity
- Firibastat expected to launch in late 2023 for difficult-to-treat/resistant hypertension.
- Gross cash of €24.9
Humana Foundation Donates $200,000 to Recovery Efforts for Louisianans Impacted by Hurricane Ida
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $200,000 to the recovery and relocation efforts for those impacted by Hurricane Ida in
AMN Healthcare to Hold Third Quarter 2021 Earnings Conference Call on Thursday, November 4, 2021
AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations, has scheduled a conference call to discuss its third quarter 2021
Waters Corporation Appoints John M. Ballbach to Board of Directors
Waters Corporation (NYSE:WAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM
NanoString to Release Third Quarter 2021 Operating Results and Host Conference Call on Tuesday, November 9, 2021
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release third quarter 2021
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Louisville Nonprofits Awarded $1.8 Million Through the Humana Foundation’s Community Partners Program
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is awarding $1.8 million to several nonprofit organizations in Louisville as part of its ongoing Community
Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2021 financial results after market close on Thursday, October 28, 2021. Management will hold a conference call
Acadia Healthcare Announces Retirement of Chief Executive Officer
The Board of Directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that Debbie Osteen will retire as CEO. Ms. Osteen will continue to serve on Acadia’s Board of Directors and
Pulse Biosciences Appoints Laureen DeBuono to Its Board of Directors
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment
Premier, Inc. to Report Fiscal 2022 First-Quarter Results and Host Conference Call on November 2, 2021
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2022 first quarter on Tuesday, November 2, 2021, at approximately 6:30 a.m. EDT. The company will
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)
LivaNova to Host Conference Call for Third Quarter 2021 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2021 results on Wednesday, November 3, 2021 at 12
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Novocure to Report Third Quarter 2021 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management
Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that a poster describing